A point mutation in the RNA-binding domain I results in decrease of PKR activation in acute lymphoblastic leukemia

Area of Science:

• Molecular Biology
• Oncology
• Virology

Background:

• RNA-dependent protein kinase (PKR) is crucial for interferon-mediated antiviral activity and influences cell growth, differentiation, and apoptosis.
• The tumor suppressor role of PKR remains controversial, with its RNA-binding domains (RBD-I and RBD-II) being critical for activation and function.
• Mutations in PKR's RNA-binding domains have not been previously reported in patient tumor cells.

Purpose of the Study:

• To investigate mutations in the RBD-I and RBD-II of the PKR gene in children diagnosed with acute lymphoblastic leukemia (ALL).
• To determine if identified mutations affect PKR's RNA-binding capability and activation.
• To explore the potential role of PKR mutations in the pathogenesis of pediatric ALL.

Main Methods:

• RNA extraction from bone marrow samples of 15 pediatric ALL patients (5 T-lineage, 10 B-lineage).
• cDNA synthesis followed by PCR amplification of PKR's RBD-I and RBD-II sequences.
• Cloning and sequencing of PCR products to identify point mutations.

Main Results:

• A single point mutation (cDNA nt 50 A --> G, resulting in 17 Tyr-->Cys) was identified in RBD-I of PKR from a T-cell lineage ALL patient.
• Activation of the identified PKR mutant by polyinosinic acid:polycytidylic acid (poly I:C) was impaired compared to wild-type PKR.
• This represents the first reported instance of a mutation in PKR's RBD-I within tumor cells directly obtained from patients.

Conclusions:

• A specific point mutation in PKR's RBD-I was detected in a pediatric T-cell ALL case.
• The identified mutation impairs PKR activation, suggesting a potential role in leukemic cell development.
• Further research is necessary to fully elucidate the contribution of this PKR mutation to ALL formation and progression.